Tiziana Life Sciences has applied for a grant from the ALS Association to fund an early-stage clinical trial testing intranasal foralumab as a potential therapy for amyotrophic lateral sclerosis (ALS). The association invited the company to apply for the grant, which is offered under the Hoffman…
Amid the busyness of last month’s ALS awareness activities, I almost missed learning about the debut of a special movie that I was quite involved with during its early stages. My friend’s email opened with, “Were your ears ringing last night?” That made me sit up straight. She told…
Eli Lilly has acquired the global exclusive rights to develop and market QRL-204, QurAlis’ investigational therapy for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) that’s designed to restore UNC13A function in nerve cells. UNC13A is an essential regulator of neurotransmitter release at synapses, a key process…
The U.S. Department of Defense (DoD) has awarded more than $2 million to help Pathmaker Neurosystems conduct a second clinical trial of its MyoRegulator — an experimental, noninvasive nerve modulating device — in people with amyotrophic lateral sclerosis (ALS). “We are very pleased to have…
An advisory committee of the European Medicines Agency (EMA) is leaning against recommending the conditional approval of AB Science’s masitinib as an oral add-on treatment for amyotrophic lateral sclerosis (ALS), the company has announced in a press release. The Committee for Medicinal Products for Human Use (CHMP)…
Last January, my sister-in-law asked what our plans were for my daughter Sara’s high school graduation. She wondered if she, my mother-in-law, and my husband’s siblings should plan to come for the commencement ceremony or a graduation party some other weekend. My husband Todd’s breathing is so compromised due to…
Increasing levels of the MIF protein may be a promising therapeutic strategy for slowing disease progression in amyotrophic lateral sclerosis (ALS), a study found. This approach in a mouse model of ALS with mutations in the SOD1 gene preserved motor function and prolonged survival, while lowering neuroinflammation and restoring…
Spinogenix will soon launch a Phase 1/2 clinical trial in the U.S. to test its investigational small molecule SPG302 in people with amyotrophic lateral sclerosis (ALS). The trial, which will assess the medication’s safety, tolerability, and pharmacological properties when given as a once-daily pill, comes after The U.S.
The ALS Association has selected InnoVision Marketing Group as its agency of record for creating media campaigns to raise awareness of amyotrophic lateral sclerosis (ALS) and the association’s mission of improving the lives of people with ALS. InnoVision, which has previously collaborated with the nonprofit on specific initiatives…
Clene Nanomedicine has nearly doubled the enrollment cap for a soon-to-launch expanded access program (EAP) to allow more patients to receive CNM-Au8 — its investigational treatment for amyotrophic lateral sclerosis (ALS) — outside of clinical trials. Also known as a compassionate use program, the EAP will…
Get regular updates to your inbox.
